reslizumab
National Institutes of Health
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Abstract Objectives: We aimed to assess the cost-utility of reslizumab for patients with severe eosinophilic asthma uncontrolled…
Abstract Introduction: Poorly controlled severe eosinophilic asthma is difficult and costly to manage. Reslizumab, an add-on…
Background: For patients (pts) with inadequately controlled eosinophilic asthma (ICEA), intravenous administration of reslizumab…
Purpose of review The inflammatory makeup of severe asthma is heterogeneous. Identification of the predominant cellular endotype…
Introduction: Clinical benefits of 100 mg SC Mepolizumab are modest when sputum eosinophilia was not controlled (CEA 2016;46:793…
Reslizumab (Cinqair®) is a humanised monoclonal interleukin-5 (IL-5) antibody developed by Teva that has been approved in the USA…
Asthma is the most common chronic respiratory disease in the USA. A subset of patients with asthma have refractory symptoms…
The starting point for this drug was the growing realization that eosinophils appeared to be associated with a severe form of…
Introduction: Patients with severe eosinophilic asthma have an unmet need for novel and efficacious treatments. Reslizumab is one…
Peripheral blood eosinophilia and eosinophilic lung inflammation are common in a variety of pulmonary conditions, including…